Skip to content
10-Q

Quarterly Report

Bio-Rad Laboratories, Inc. BIO BIO-B

0000012208-26-000035

← back to feed
Filed
Apr 30, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 26.96M sh
Shares Diluted Q1 2026 · Mar 31, 2025 27.96M sh
Stock Repurchased Q1 2026 · Mar 31, 2026 $47.8M
Stock Repurchased Q1 2026 · Mar 31, 2025 $101.9M
Capex Q1 2026 · Mar 31, 2026 $30M
Capex Q1 2026 · Mar 31, 2025 $34.4M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $108.1M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $129.9M
Long Term Debt Q1 2026 · Mar 31, 2026 $802.9M
Long Term Debt Q1 2026 · Dec 31, 2025 $1.2B
Short Term Investments Q1 2026 · Mar 31, 2026 $1.06B
Short Term Investments Q1 2026 · Dec 31, 2025 $1.01B
Cash And Equivalents Q1 2026 · Mar 31, 2026 $507.2M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $529.8M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $521.4M
Stockholders Equity Q1 2026 · Mar 31, 2026 $6.85B
Stockholders Equity Q1 2026 · Dec 31, 2025 $7.45B
Stockholders Equity Q1 2026 · Mar 31, 2025 $6.68B
Stockholders Equity Q1 2026 · Dec 31, 2024 $6.57B
Current Liabilities Q1 2026 · Mar 31, 2026 $917M
Current Liabilities Q1 2026 · Dec 31, 2025 $517M
Total Liabilities Q1 2026 · Mar 31, 2026 $2.94B
Total Liabilities Q1 2026 · Dec 31, 2025 $3.12B
Current Assets Q1 2026 · Mar 31, 2026 $2.94B
Current Assets Q1 2026 · Dec 31, 2025 $2.91B
Total Assets Q1 2026 · Mar 31, 2026 $9.79B
Total Assets Q1 2026 · Dec 31, 2025 $10.58B
Eps Diluted Q1 2026 · Mar 31, 2026 −$19.55
Eps Diluted Q1 2026 · Mar 31, 2025 $2.29
Eps Basic Q1 2026 · Mar 31, 2026 −$19.55
Eps Basic Q1 2026 · Mar 31, 2025 $2.29
Sga Expense Q1 2026 · Mar 31, 2026 $212.4M
Sga Expense Q1 2026 · Mar 31, 2025 $208.8M
Rd Expense Q1 2026 · Mar 31, 2026 $62.9M
Rd Expense Q1 2026 · Mar 31, 2025 $73.5M
Net Income Q1 2026 · Mar 31, 2026 −$527.1M
Net Income Q1 2026 · Mar 31, 2025 $64M
Operating Income Q1 2026 · Mar 31, 2026 $34.1M
Operating Income Q1 2026 · Mar 31, 2025 $23.7M
Gross Profit Q1 2026 · Mar 31, 2026 $309.4M
Gross Profit Q1 2026 · Mar 31, 2025 $306M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $282.7M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $279.4M
Revenue Q1 2026 · Mar 31, 2026 $592.1M
Revenue Q1 2026 · Mar 31, 2025 $585.4M